EUVIMEDEUVIMED entdecken
Crossref

Intelligent POCT for ovarian cancer: Dual-biomarker detection combined with ROMA risk assessment using selenium nanoparticle

Weiqi Xie, Jinbo Wu, Xiaoyi Xie, Mengli Wu, Menghan Zhang, Mengyao Zhang, Xiaoquan Li, Li Wang, Lanju Wang, Zhigang Liu, Zhizeng Wang, Chunxia Chen

Analytica Chimica Acta · 2026-06 · 1404 · 345434

DOI: 10.1016/j.aca.2026.345434 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Analytica Chimica Acta, 2026-06. Verfasst von Weiqi Xie und 11 weiteren Autor:innen. Beteiligte Einrichtung: Joint National Laboratory for Antibody Drug Engineering, The First Affiliated Hospital of Henan University, Henan University, Kaifeng, 475004, People…. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Selenium, Biomarkers, Tumor, Nanoparticles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Science and Technology Department of Henan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The early diagnosis of ovarian cancer remains dissolved due to the lack of detection methods that are sensitive, rapid and accessible. To address this clinical challenge, this study developed an innovative diagnostic platform integrating a novel selenium nanoparticles (SeNPs) probe, dual-biomarker (CA125 and HE4) detection and intelligent analysis system. The detection limits for CA125 and HE4 were determined to be 35 U/mL and 100 pmol/L respectively, and no cross-reactivity was observed. Capitalizing on computer vision and AI prompt engineering technology, this study implemented smartphone-based image acquisition combined with AI-assisted analysis. The results of 360 clinical samples testing indicated that the coincidence rate of this kit with chemiluminescence method was over 95%, and the AUC of the combined detection of dual markers reached 0.914. By integrating the ROMA algorithm, the risk probability of ovarian cancer can be calculated in real time based on the test results and the patient's menopausal status, enabling quantitative risk assessment. This study provides a stable, highly specific, cost-effective and clinically decision supported point-of-care diagnostic solution for the early screening of ovarian cancer, promoting the development of POCT technology towards intelligence and precision.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsSeleniumBiomarkers, TumorNanoparticlesCA-125 AntigenPoint-of-Care SystemsProteinsFemaleHumansWAP Four-Disulfide Core Domain Protein 2Risk AssessmentAlgorithmsMembrane Proteins

Stichwörter der Autor:innen

Dual biomarkerIntelligent detectionOvarian cancerSeNPs

Substanzen

SeleniumBiomarkers, TumorWAP Four-Disulfide Core Domain Protein 2WFDC2 protein, humanCA-125 AntigenProteinsMUC16 protein, humanMembrane Proteins

Autor:innen und Institutionen

  • Joint National Laboratory for Antibody Drug Engineering, The First Affiliated Hospital of Henan University, Henan University, Kaifeng, 475004, People's Republic of China.
  • Department of Clinical Laboratory, Chongqing University FuLing Hospital, Chongqing, 408000, People's Republic of China.
  • Henan Province Engineering Technology Research Center of Rapid-Accuracy Medical Diagnostics, Department of Clinical Laboratory, The First Affiliated Hospital of Henan University, Henan University, Kaifeng, 475000, Peopl…
  • Department of Blood Transfusion, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, People's Republic of China.
  • Department of Laboratory Medicine, Chongqing Center for Clinical Laboratory, Chongqing Academy of Medical Sciences, Chongqing General Hospital, School of Medicine, Chongqing University, Chongqing, 401147, People's Repub…
  • Joint National Laboratory for Antibody Drug Engineering, The First Affiliated Hospital of Henan University, Henan University, Kaifeng, 475004, People's Republic of China. Electronic address: ccxcvd@henu.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation
  • Science and Technology Department of Henan Province
  • Department of Science and Technology of Henan Province

Zitieren

APA

Xie, W., Wu, J., Xie, X., Wu, M., Zhang, M., Zhang, M., Li, X., Wang, L., Wang, L., Liu, Z., Wang, Z., & Chen, C. (2026). Intelligent POCT for ovarian cancer: Dual-biomarker detection combined with ROMA risk assessment using selenium nanoparticle. Analytica Chimica Acta, 1404, 345434. https://doi.org/10.1016/j.aca.2026.345434

Vancouver

Xie W, Wu J, Xie X, Wu M, Zhang M, Zhang M, et al. Intelligent POCT for ovarian cancer: Dual-biomarker detection combined with ROMA risk assessment using selenium nanoparticle. Analytica Chimica Acta. 2026;1404:345434. doi:10.1016/j.aca.2026.345434

BibTeX
@article{Xie2026,
  author = {Xie, Weiqi and Wu, Jinbo and Xie, Xiaoyi and Wu, Mengli and Zhang, Menghan and Zhang, Mengyao and Li, Xiaoquan and Wang, Li and Wang, Lanju and Liu, Zhigang and Wang, Zhizeng and Chen, Chunxia},
  title = {Intelligent POCT for ovarian cancer: Dual-biomarker detection combined with ROMA risk assessment using selenium nanoparticle},
  journal = {Analytica Chimica Acta},
  year = {2026},
  volume = {1404},
  pages = {345434},
  doi = {10.1016/j.aca.2026.345434}
}
Kostenlos starten →